FI2124547T4 - Syövän hoitomenetelmä - Google Patents

Syövän hoitomenetelmä

Info

Publication number
FI2124547T4
FI2124547T4 FIEP08729939.2T FI08729939T FI2124547T4 FI 2124547 T4 FI2124547 T4 FI 2124547T4 FI 08729939 T FI08729939 T FI 08729939T FI 2124547 T4 FI2124547 T4 FI 2124547T4
Authority
FI
Finland
Prior art keywords
cancer
use according
leukemia
treatment
lymphoma
Prior art date
Application number
FIEP08729939.2T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Connie Erickson-Miller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI2124547(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI2124547T4 publication Critical patent/FI2124547T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP08729939.2T 2007-02-16 2008-02-15 Syövän hoitomenetelmä FI2124547T4 (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
PCT/US2008/054046 WO2008101141A2 (en) 2007-02-16 2008-02-15 Cancer treatment method

Publications (1)

Publication Number Publication Date
FI2124547T4 true FI2124547T4 (fi) 2025-07-29

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP08729939.2T FI2124547T4 (fi) 2007-02-16 2008-02-15 Syövän hoitomenetelmä

Country Status (28)

Country Link
US (2) US20100075928A1 (enExample)
EP (1) EP2124547B3 (enExample)
JP (1) JP5511391B2 (enExample)
KR (1) KR101447763B1 (enExample)
CN (1) CN101662937B (enExample)
AR (1) AR065348A1 (enExample)
AU (1) AU2008216106C1 (enExample)
BR (1) BRPI0807940B8 (enExample)
CA (1) CA2678358C (enExample)
CR (1) CR10997A (enExample)
DK (1) DK2124547T6 (enExample)
EA (1) EA017715B1 (enExample)
ES (1) ES2675070T7 (enExample)
FI (1) FI2124547T4 (enExample)
HU (1) HUE038563T2 (enExample)
IL (2) IL200319A (enExample)
MA (1) MA31202B1 (enExample)
MX (1) MX2009008822A (enExample)
NZ (1) NZ579068A (enExample)
PE (1) PE20081784A1 (enExample)
PL (1) PL2124547T5 (enExample)
PT (1) PT2124547T (enExample)
SI (1) SI2124547T2 (enExample)
TR (1) TR201809010T4 (enExample)
TW (1) TW200906393A (enExample)
UY (1) UY30915A1 (enExample)
WO (1) WO2008101141A2 (enExample)
ZA (1) ZA200905532B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101888841B (zh) * 2007-10-09 2012-09-26 宾夕法尼亚大学理事会 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
CA2763768A1 (en) 2009-05-29 2010-12-02 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
JP2013538810A (ja) * 2010-09-01 2013-10-17 ノバルティス アーゲー Ｈｄａｃ阻害剤と血小板減少症薬との組合せ
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
SG10201913416PA (en) * 2016-05-06 2020-03-30 Taris Biomedical Llc Method of treating lower tract urothelial cancer
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
US7026334B1 (en) * 1999-07-26 2006-04-11 Shionogi & Co., Ltd. Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism
EP2087907B1 (en) * 1999-11-10 2014-09-24 Innatus Corporation Method and system to remove cytokine inhibitor in patients
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) * 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
EP1284997B1 (en) * 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
CA2435143A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Halogen compounds having thrombopoietin receptor agonism
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
ES2610611T3 (es) * 2002-01-18 2017-04-28 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
AR040083A1 (es) * 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2583764C (en) * 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
BRPI0620532A2 (pt) 2005-11-23 2011-11-16 Ligand Pharm Inc compostos e métodos para modular a atividade de trombopoietina
US20100063301A1 (en) 2006-03-15 2010-03-11 Ligand Pharmaceuticals Inc Synthesis of thrombopoietin activity modulating compounds

Also Published As

Publication number Publication date
UY30915A1 (es) 2008-09-02
AU2008216106C1 (en) 2025-11-13
IL238394A0 (en) 2015-06-30
MX2009008822A (es) 2009-08-28
IL238394B (en) 2018-05-31
WO2008101141A2 (en) 2008-08-21
TR201809010T4 (tr) 2018-07-23
CN101662937B (zh) 2014-03-12
EP2124547A2 (en) 2009-12-02
CN101662937A (zh) 2010-03-03
CA2678358C (en) 2015-12-08
WO2008101141A3 (en) 2008-10-16
EP2124547B3 (en) 2025-06-18
NZ579068A (en) 2012-05-25
DK2124547T3 (en) 2018-07-16
EP2124547B2 (en) 2025-04-16
EA200970776A1 (ru) 2010-02-26
TW200906393A (en) 2009-02-16
EP2124547B1 (en) 2018-03-28
SI2124547T2 (sl) 2025-07-31
IL200319A0 (en) 2010-04-29
KR101447763B1 (ko) 2014-10-07
PL2124547T5 (pl) 2025-08-04
CA2678358A1 (en) 2008-08-21
BRPI0807940B8 (pt) 2021-05-25
AR065348A1 (es) 2009-06-03
US20100075928A1 (en) 2010-03-25
BRPI0807940A2 (pt) 2013-07-30
BRPI0807940B1 (pt) 2020-10-27
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
PE20081784A1 (es) 2009-01-25
ES2675070T7 (en) 2025-08-06
ZA200905532B (en) 2010-04-28
AU2008216106A1 (en) 2008-08-21
IL200319A (en) 2015-05-31
DK2124547T6 (da) 2025-09-01
DK2124547T4 (da) 2025-08-04
HUE038563T2 (hu) 2018-10-29
EA017715B1 (ru) 2013-02-28
AU2008216106B2 (en) 2013-07-11
AU2008216106B9 (en) 2013-09-05
MA31202B1 (fr) 2010-02-01
EP2124547A4 (en) 2010-05-05
JP2010519221A (ja) 2010-06-03
CR10997A (es) 2009-10-16
PL2124547T3 (pl) 2018-08-31
JP5511391B2 (ja) 2014-06-04
PT2124547T (pt) 2018-07-04
SI2124547T1 (en) 2018-08-31
ES2675070T3 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
FI2124547T4 (fi) Syövän hoitomenetelmä
JP2011126896A5 (enExample)
Zhang et al. Targeting the Wnt/β-catenin signaling pathway in cancer
Abdelsalam et al. Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
Cao et al. Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: a novel class of potent tubulin polymerization inhibitors
Akhtar et al. Recent progress of benzimidazole hybrids for anticancer potential
ME02663B (me) Derivati benzimidazola kao inhibitori pi3 kinaze
Alanazi et al. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: Design, synthesis, and in silico studies
KR101345002B1 (ko) 제약 화합물
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
Yadav et al. The recent development of tetrahydro-quinoline/isoquinoline based compounds as anticancer agents
JP2010518110A5 (enExample)
JP2010528026A5 (enExample)
AU2013235425B2 (en) Inhibition of MCL-1 and/or BFL-1/A1
AU2012322660B2 (en) Pyrazol-3-ones that activate pro-apoptotic BAX
JP2009516653A5 (enExample)
HRP20140790T1 (hr) Inhibitori aktivnosti akt
Walayat et al. An insight into the therapeutic potential of piperazine-based anticancer agents
JPWO2021085653A5 (enExample)
AU2013302766B2 (en) Benzodiazepines for treating small cell lung cancer
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
JP2010519221A5 (enExample)
JP2014530881A5 (enExample)
JP2013504582A5 (enExample)
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1